PharmaCyte Biotech, a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, has signed a research services agreement and a consulting contract with the University of Technology Sydney (UTS) in Australia. Both of these contracts concern the development of PharmaCyte Biotech’s treatment for insulin-dependent diabetes that is comprised of proprietary human non-pancreatic insulin-p...